

UCSF

UC San Francisco Previously Published Works

Title

Epidemiology of mild traumatic brain injury and neurodegenerative disease

Permalink

<https://escholarship.org/uc/item/60f0b8zc>

Journal

Molecular and Cellular Neuroscience, 66(Pt B)

ISSN

1044-7431

Authors

Gardner, Raquel C

Yaffe, Kristine

Publication Date

2015-05-01

DOI

10.1016/j.mcn.2015.03.001

Peer reviewed



Published in final edited form as:

Mol Cell Neurosci. 2015 May ; 66(0 0): 75–80. doi:10.1016/j.mcn.2015.03.001.

Epidemiology of mild traumatic brain injury and neurodegenerative disease

Raquel C. Gardner, MD^a and Kristine Yaffe, MD^{a,b,c}

^aDepartment of Neurology, University of California San Francisco, CA

^bSan Francisco Veterans Affairs Medical Center, CA

^cDepartments of Epidemiology/Biostatistics and Psychiatry, University of California San Francisco, CA

Abstract

Every year an estimated 42 million people worldwide suffer a mild traumatic brain injury (MTBI) or concussion. More severe traumatic brain injury (TBI) is a well-established risk factor for a variety of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Recently, large epidemiological studies have additionally identified MTBI as a risk factor for dementia. The role of MTBI in risk of PD or ALS is less well established. Repetitive MTBI and repetitive sub-concussive head trauma has been linked to increased risk for a variety of neurodegenerative diseases including chronic traumatic encephalopathy (CTE). CTE is a unique neurodegenerative tauopathy first described in boxers but more recently described in a variety of contact sport athletes, military veterans, and civilians exposed to repetitive MTBI. Studies of repetitive MTBI and CTE have been limited by referral bias, lack of consensus clinical criteria for CTE, challenges of quantifying MTBI exposure, and potential for confounding. The prevalence of CTE is unknown and the amount of MTBI or sub-concussive trauma exposure necessary to produce CTE is unclear. This review will summarize the current literature regarding the epidemiology of MTBI, post-TBI dementia and Parkinson's disease, and CTE while highlighting methodological challenges and critical future directions of research in this field.

Keywords

Chronic traumatic encephalopathy; Traumatic brain injury; Mild traumatic brain injury; Concussion; Neurodegenerative disease; Epidemiology

© 2015 Published by Elsevier Inc.

Corresponding author: Raquel C. Gardner, MD, 4150 Clement St., Neurology #127, San Francisco, CA 94121, raquel.gardner@ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

There is mounting epidemiological evidence that moderate or severe traumatic brain injury (TBI) is an important risk factor for neurodegenerative diseases such as Alzheimer's disease (AD)^{1, 2} and Parkinson's disease (PD).³ Relatively fewer studies have assessed the association specifically between mild TBI (MTBI) and neurodegenerative diseases, and thus this association is not as well established.^{4, 5} Since the highly publicized report of a series of autopsy cases of professional American football players with chronic traumatic encephalopathy (CTE),^{6, 7} however, there has been a resurgence of interest in unraveling the potential link between MTBI and neurodegenerative disease including CTE. This resurgence of interest has led to a number of recent studies that have investigated the risk of neurodegenerative diseases following MTBI or prevalence of neurodegenerative diagnoses or suggestive symptoms among individuals with high levels of exposure to repetitive MTBI. While this burgeoning field is rapidly making important new discoveries that are largely in support of a link between MTBI – particularly repetitive MTBI – and neurodegeneration, many questions remain. What is the population prevalence of CTE? What is the long-term risk of playing contact sports? What is the long-term risk of combat deployment and blast injury? How many head traumas (concussive or otherwise) are necessary to produce CTE? What are the biological mechanisms or risk factors?

Currently, CTE is a neuropathological diagnosis that cannot be made during life. Thus, all modern studies of CTE have been based on autopsy series while most large epidemiological studies of post-TBI neurodegenerative diseases have been based on clinical diagnoses of common neurodegenerative syndromes. Thus, the relationship between CTE neuropathology and post-TBI neurodegenerative syndromes (AD, PD, frontotemporal dementia, ALS) is unknown. It is plausible, for example, that some cases of clinically-diagnosed post-TBI AD, PD, or ALS actually reflect CTE neuropathology (or vice versa, as a significant minority of cases of CTE have had additional co-occurring neuropathologies⁸). This review will summarize the current literature regarding the epidemiology of MTBI, the epidemiology of post-TBI dementias and Parkinson's disease, and the epidemiology of CTE. Where appropriate, important avenues for future research will be highlighted.

What is MTBI?

The terms MTBI and concussion are often used interchangeably. Some would argue that these terms represent fundamentally different concepts and that concussion is a type of MTBI.⁹ Sub-concussive injury refers to a traumatic impact to the head that does not result in any immediately appreciable clinical symptoms.¹⁰ According to the World Health Organization Collaborating Center Task Force and the Centers for Disease Control and Prevention (CDC):

“MTBI is an acute brain injury resulting from mechanical energy to the head from external physical forces. Operational criteria for clinical identification include: (1) one or more of the following: confusion or disorientation, loss of consciousness for 30 minutes or less, post-traumatic amnesia for less than 24 hours, and/or other transient neurological abnormalities such as focal signs, seizure, and intracranial lesion not requiring surgery; and (2) Glasgow Coma Scale score of 13-15 after 30

minutes post-injury or later upon presentation for healthcare. (3) These manifestations of MTBI must not be due to drugs, alcohol, medications, caused by other injuries or treatment for other injuries (e.g. systemic injuries, facial injuries or intubation), caused by other problems (e.g. psychological trauma, language barrier or coexisting medical conditions) or caused by penetrating craniocerebral injury.”¹¹

The CDC has proposed specific International Classification of Diseases 9 (ICD-9) codes for the classification of MTBI.¹² These definitions are not yet universally used. A recent study⁴ by the International Collaboration on Mild Traumatic Brain Injury systematically reviewed the MTBI diagnostic criteria used by the “best-evidence literature” pertaining to MTBI from 2001 through 2012. Among the 101 studies included in this review, there were more than 50 different MTBI definitions used. In light of this lack of consensus, workshops coordinated by the National Institute of Neurological Disorders and Stroke (NINDS), Department of Defense (DOD), and the National Institute on Disability and Rehabilitation Research (NIDRR) have established a multidisciplinary effort to develop TBI Common Data Elements (TBI-CDEs),¹³ which were first published in 2010 and then revised in 2012. Thus, all data presented in the remainder of this review must be interpreted in this context.

How common is MTBI and repetitive MTBI?

MTBI is extremely common. It is estimated that 100 to 300 per 100,000 people seek medical attention for MTBI annually worldwide.¹⁴ Because many people with MTBI may not seek medical attention,¹⁵ it is likely that the true global population incidence of MTBI exceeds 600 per 100,000 people annually (or roughly 42 million people worldwide every year), with most cases being due to falls or motor vehicle collisions.¹⁴ The prevalence of repetitive MTBI is less clear. It is known that prior TBI is a risk factor for future TBI,¹⁶ though risk specifically pertaining to MTBI is not known.

Certain sub-populations such as contact sport athletes (including American football, boxing, ice hockey, mixed martial arts, and soccer), military personnel, and victims of domestic violence are at particularly high risk for suffering MTBI, repetitive MTBI, and repetitive sub-concussive head trauma. Interestingly, TBI exposure across many of these high-risk populations has not remained stable over time – a phenomenon known to epidemiologists as a “secular trend.” For example, a study of professional boxers in the United Kingdom and Australia found that from 1930 to 2003 the average professional boxer's career duration dropped nearly 75% (from 19 to 5 years) while the average number of career bouts dropped 96% (from 336 to 13).¹⁷ This reduction in exposure over time paralleled increases in medical oversight and raises the possibility that the quality of chronic neurologic sequelae of boxing may change over time as well.¹⁸ Similarly, professional American football has changed dramatically over the past few decades, with increasing medical oversight and changes to protective gear and rules of play aimed specifically at improving player safety. It is possible, however, that increased body padding and improved helmets could, paradoxically, increase the frequency and severity of traumatic hits sustained by players due to an increased sense of personal safety (i.e. “risk compensation”).¹⁹ Modern tracking devices have found that players currently sustain thousands of sub-concussive hits to the head during a single season.^{20, 21} Lastly, among military veterans, mortality following TBI

has declined dramatically since the Vietnam war, leaving an increasing number of military veterans living with sequelae of TBI and potentially being at heightened risk of repeat TBI. War tactics have also changed such that blast injuries, which frequently result in mild-TBI (or sub-concussive head trauma), are extremely common. A recent survey of deployed troops in Operation Iraqi Freedom and Operation Enduring Freedom found that 17% reported MTBI during deployment, and of these, 59% reported more than one MTBI.²² Thus, some secular trends may be associated with reduced exposure to repetitive MTBI while other secular trends may be associated with heightened exposure.

Apart from secular trends, there may be cohort effects between different sports and different types of military-related MTBI.²³ That is, the biomechanics and resultant neuronal injury of an MTBI sustained by a football player may differ from those incurred by a boxer or blast-exposed military veteran. Along these lines, early reports of CTE in boxers more frequently reported parkinsonism as a presenting symptom²⁴ compared to modern series of CTE comprised mainly of non-boxers.²⁵

These estimated statistics, secular trends, and cohort effects highlight the critical importance of ongoing research to better characterize and quantify MTBI exposure, particularly among specific high-risk populations.

Does TBI increase risk for neurodegeneration?

Many studies have assessed risk of common neurodegenerative diseases following TBI. Meta-analyses of many of these prior studies have shown a significantly increased risk associated with history of TBI for the development of AD,^{1, 2} PD,³ and ALS.²⁶ Two studies have additionally identified TBI as a risk factor for frontotemporal dementia.^{27, 28} Thus, while there is solid epidemiological evidence in support of TBI as a risk factor for many neurodegenerative diseases, additional research is needed to answer a number of outstanding questions. For example, since many prior studies have been based on retrospective determination of TBI, large well-powered prospective confirmatory studies are needed. Creative population-based approaches need to be developed to capture cases of TBI that may not present to medical attention and may differ systematically from those who do.¹⁵ The selection of controls requires careful consideration in order to reduce the likelihood of confounding or reverse-causation²⁹ (e.g. if a patient suffers a TBI due to incipient neurodegenerative disease or if patients prone to TBI differ systematically from those not prone to TBI). Lastly, a few exciting studies have found that specific genes or other exposures may independently or synergistically increase risk for neurodegeneration after TBI^{30, 31, 32} (see risk factors, below), highlighting the need for further studies of risk modifiers or mediators of post-TBI neurodegenerative diseases.

Does MTBI increase risk for neurodegeneration?

The majority of prior epidemiological studies assessing risk of neurodegenerative diseases following TBI have focused either on risk imparted by a TBI of any severity or of risk imparted by a moderate or severe TBI. For example, two systematic reviews of risk of dementia following MTBI^{33, 34} that jointly covered the world literature from 1980 through 2012 identified only four qualifying studies.³⁵⁻³⁸ Of these four studies, two reported a

dementia, or even ALS. Recently reported cases have typically developed progressive neurobehavioral symptoms years or decades following exposure to MTBI,²⁵ although at least one incipient case of CTE has been reported in a high-school football player who died unexpectedly.⁴⁹ Because CTE is a neuropathological diagnosis, the prevalence of CTE in the general population is unknown. To date, large population-based studies of CTE have not been possible due to the lack of consensus clinical diagnostic criteria for CTE, thus precluding diagnosis during life. Estimates of prevalence of CTE must then rely upon autopsy series of neuropathologically confirmed cases of CTE or clinical case series assessing prevalence of suggestive clinical syndromes in populations exposed to repetitive MTBI such as professional contact sport athletes or military veterans. Furthermore, among epidemiological studies reporting an association between TBI (or MTBI or repetitive MTBI) and neurodegenerative syndromes that lack autopsy-confirmation, the degree to which these clinical syndromic diagnoses reflect true PD, AD, frontotemporal dementia, ALS, CTE, or any combination of the above, remains unknown. Table 1 outlines just a few of the methodological challenges facing epidemiological studies of CTE. Table 2 provides definitions of pertinent epidemiological terminology.

An association between repetitive MTBI and chronic or progressive neurologic dysfunction was first reported in the medical literature by Harrison S. Martland in his 1928 report, "Punch Drunk."⁵⁰ The report consists of one detailed case description of a professional boxer who retired at the age of 23, after 7 years in the ring, due to left hand tremor and gait unsteadiness. Despite retirement, this patient's symptoms progressed. By age 38, his symptoms were indistinguishable from PD. Although Martland does not report any specific data in this regard, and had personally examined only five symptomatic boxers, he stated that "almost 50 percent of fighters" develop progressive impairments that usually begin with slightly "flopping" of one foot or leg while walking or slight gait unsteadiness which may then be followed by periods of slight mental confusion as well as bradykinesia and may, in the most severe cases, progress to severe parkinsonism and mental deterioration.

Subsequent to this report, others began publishing similar case reports or small case series of neurologic sequelae of boxing.⁵¹⁻⁵³ The syndrome became known as dementia pugilistica⁵² as it was believed to occur primarily in boxers. On review of some of these early cases, it seems likely that at least some cases reflected chronic neurologic deficits due to acute brain contusions or hemorrhages sustained during a boxing bout rather than progressive neurodegenerative disorders. In the absence of medical oversight of boxing at that time, high-resolution neuroimaging studies, or detailed neuropathological descriptions of dementia pugilistica, however, a determination of underlying etiology in these early cases was not possible. It was not until the 1960s and 70s that autopsy reports of a unique degenerative neuropathology, eventually termed CTE, was correlated with the syndrome of dementia pugilistica.^{24, 54}

In 1969, Roberts published a highly cited clinical study of 250 randomly sampled boxers from a cohort of over 16,000 boxers registered in the UK between 1929 and 1955 that reported that 17% of sampled boxers showed neurologic deficits attributable to boxing.⁵⁵ While this early clinical study remains the best attempt to assess an unbiased population prevalence of boxing-associated neurologic sequelae, it is unclear what proportion of these

cases may have had neuropathological evidence of CTE.⁵⁶ Lastly, given dramatic changes in rules of play, medical oversight, and duration and intensity of boxing careers since these early studies were performed, extrapolation of this result to modern day boxers or other athletes, military personnel, or civilians exposed to repeated MTBI is challenging.

Since the first recognition of CTE in a professional American football player in 2005,⁶ a number of subsequent modern cases and case-series of CTE have been reported. The largest modern autopsy series to date, that included 85 patients exposed to repetitive MTBI (including 64 athletes and 21 military veterans), identified evidence of CTE in 68 patients (80%).⁸ Today, American football remains the sport most commonly associated with autopsy-proven CTE in the modern medical literature. Recent autopsy series assessing rates of CTE among former professional American football players have reported prevalence ranging from 50% to 97%,^{8, 49, 57} though all of these reports are limited by referral bias. Interestingly, however, one of these studies that included 35 former professional American football players⁸ found that the neuropathological stage of CTE significantly correlated with number of years of football exposure, lending weight to a true causal association.

Consensus clinical criteria for CTE^{58, 59} are needed in order to facilitate population-based epidemiological studies of CTE incidence and prevalence.^{54, 55} The overlap between CTE-associated symptoms and other common neurodegenerative syndromes suggests that consensus research criteria will likely require a combination of TBI exposure history, clinical features, and neuroimaging⁶⁰ or body fluid biomarkers.⁶¹ Thus, ongoing efforts to identify potentially unique clinical features of CTE and to develop and refine biomarkers of CTE are critically important. Lastly, prospective, longitudinal studies of high-risk subgroups are needed to better quantify MTBI exposure, subsequent risk of CTE, and additional risk factors for CTE, as are already underway among boxers⁶² and recently returned U.S. military veterans.⁶³

Risk Factors for Post-TBI Neurodegenerative Diseases and CTE

The absence of CTE neuropathology in some multiply-concussed professional American football players⁵⁷ as well as the absence of neurodegenerative disease in the majority of adults with a history of prior MTBI or concussion, suggests that there must be multiple additional risk and protective factors that determine whether an individual person develops a post-TBI neurodegenerative disease.

Apolipoprotein E (APOE) ϵ 4 allele, the strongest susceptibility gene for AD, is associated with modified risk for many neurodegenerative diseases following TBI.^{48, 64-67} This association between APOE allele and CTE, however, remains unclear given competing results of recent studies.^{54, 62, 64} Specific mutations in genes encoding α -synuclein have been associated with increased risk of PD after TBI^{30, 31} and this risk is augmented in a more than additive manner with exposure to paraquat-containing pesticides³² (Table 3).

It is unknown whether recreational drug or steroid use, alcohol abuse, chronic psychiatric disease, or cardiovascular risk factors modify risk of CTE, though these conditions may have been over-represented in modern autopsy series of CTE comprised largely of professional athletes. There is some evidence that TBI in children or adolescents may be

particularly morbid.^{71, 72} On the other hand, we have found that older adults are at higher risk of dementia after MTBI compared to middle-aged adults.⁴¹ These results suggest that there may be “critical periods” during which TBI may be more likely to produce chronic neurologic sequelae or neurodegeneration. Gender effects are also understudied. The vast majority of cases of CTE have been in males, presumably due to referral bias.

Summary

MTBI is extremely common affecting roughly 42 million people annually worldwide. Definitions of MTBI across studies are inconsistent, highlighting the need for ongoing efforts to develop and refine TBI common data elements. Moderate or severe TBI is an established risk factor for neurodegenerative diseases such as dementia, PD, and ALS. Recently, large epidemiological studies have reported that MTBI and repetitive MTBI are also significant risk factors for neurodegenerative diseases, but these associations are not yet as well established and require further replication. CTE is a neuropathological diagnosis that has been associated with repetitive MTBI exposure. Prevalence of CTE is unknown due to referral bias limiting autopsy studies and lack of consensus clinical criteria limiting unbiased population-based studies. Among athletes exposed to extremely high levels of repetitive MTBI or repetitive sub-concussive head traumas, such as former American football players, CTE has been reported in 50% to 97% of players that have gone to autopsy. Consensus clinical diagnostic criteria for CTE are needed. Clinical overlap between symptoms associated with CTE and other more common neurodegenerative diseases such as AD and PD suggest that CTE clinical criteria will likely require a combination of TBI history, clinical symptoms, and biomarkers. Improved quantification of MTBI exposure as well as prospective longitudinal studies of outcomes and risk factors will be critical to elucidate the actual burden of neurodegenerative diseases including CTE among athletes, military personnel, and civilians exposed to single or repetitive MTBI.

Acknowledgments

RCG is supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the San Francisco Veterans Affairs Medical Center, and the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). KY has received research support from the National Institutes of Health (NIH) via K24 AG031155, the Department of Defense via W81XWH-12-1-0581, the Department of Veterans Affairs, the California Department of Public Health, the Bright Focus Foundation, and the Alzheimer's Association.

References

1. Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. *International journal of epidemiology*. 1991; 20(Suppl 2):S28–35. [PubMed: 1833351]
2. Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *J Neurol Neurosurg Psychiatry*. 2003 Jul; 74(7):857–62. [PubMed: 12810767]
3. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. *Mov Disord*. 2013 Aug; 28(9):1222–9. [PubMed: 23609436]
4. Kristman VL, Borg J, Godbolt AK, et al. Methodological issues and research recommendations for prognosis after mild traumatic brain injury: results of the International Collaboration on Mild

- Traumatic Brain Injury Prognosis. Archives of physical medicine and rehabilitation. 2014 Mar; 95(3 Suppl):S265–77. [PubMed: 24581912]
5. Marras C, Hincapie CA, Kristman VL, et al. Systematic review of the risk of Parkinson's disease after mild traumatic brain injury: results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. Archives of physical medicine and rehabilitation. 2014 Mar; 95(3 Suppl):S238–44. [PubMed: 24581909]
 6. Omalu BI, DeKosky ST, Minster RL, Kamboh MI, Hamilton RL, Wecht CH. Chronic traumatic encephalopathy in a National Football League player. Neurosurgery. 2005 Jul; 57(1):128–34. discussion -34. [PubMed: 15987548]
 7. Omalu BI, DeKosky ST, Hamilton RL, et al. Chronic traumatic encephalopathy in a national football league player: part II. Neurosurgery. 2006 Nov; 59(5):1086–92. discussion 92-3. [PubMed: 17143242]
 8. McKee AC, Stern RA, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013 Jan; 136(Pt 1):43–64. [PubMed: 23208308]
 9. McCrory P, Meeuwisse WH, Aubry M, et al. Consensus statement on concussion in sport: the 4th International Conference on Concussion in Sport, Zurich, November 2012. Journal of athletic training. 2013 Jul-Aug; 48(4):554–75. [PubMed: 23855364]
 10. Spiotta AM, Shin JH, Bartsch AJ, Benzel EC. Subconcussive impact in sports: a new era of awareness. World neurosurgery. 2011 Feb; 75(2):175–8. [PubMed: 21492686]
 11. Carroll LJ, Cassidy JD, Holm L, Kraus J, Coronado VG. Injury WHOCTFoMTB. Methodological issues and research recommendations for mild traumatic brain injury: the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine. 2004 Feb.(43 Suppl):113–25.
 12. National Center for Injury Prevention. Report to Congress Mild Traumatic Brain Injury in the United States: Steps to Prevent a Serious Public Health Problem. Atlanta: Centers for Disease Control and Prevention; 2003.
 13. NINDS Common Data Elements: Traumatic Brain Injury. [cited 2014 October 15] National Institutes of Neurological Diseases and Stroke. Available from: http://www.commondataelements.ninds.nih.gov/TBI.aspx-tab=Data_Standards
 14. Cassidy JD, Carroll LJ, Peloso PM, et al. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine. 2004 Feb.(43 Suppl):28–60.
 15. Setnik L, Bazarian JJ. The characteristics of patients who do not seek medical treatment for traumatic brain injury. Brain injury : [BI]. 2007 Jan; 21(1):1–9.
 16. Dams-O'Connor K, Gibbons LE, Bowen JD, McCurry SM, Larson EB, Crane PK. Risk for late-life re-injury, dementia and death among individuals with traumatic brain injury: a population-based study. J Neurol Neurosurg Psychiatry. 2013 Feb; 84(2):177–82. [PubMed: 23172868]
 17. Clausen H, McCrory P, Anderson V. The risk of chronic traumatic brain injury in professional boxing: change in exposure variables over the past century. British journal of sports medicine. 2005 Sep; 39(9):661–4. discussion 4. [PubMed: 16118306]
 18. Gardner A, Iverson GL, McCrory P. Chronic traumatic encephalopathy in sport: a systematic review. British journal of sports medicine. 2013 Jun 26.
 19. Hagel B, Meeuwisse W. Risk compensation: a “side effect” of sport injury prevention? Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine. 2004 Jul; 14(4):193–6. [PubMed: 15273524]
 20. Crisco JJ, Fiore R, Beckwith JG, et al. Frequency and location of head impact exposures in individual collegiate football players. Journal of athletic training. 2010 Nov-Dec; 45(6):549–59. [PubMed: 21062178]
 21. Greenwald RM, Gwin JT, Chu JJ, Crisco JJ. Head impact severity measures for evaluating mild traumatic brain injury risk exposure. Neurosurgery. 2008 Apr; 62(4):789–98. discussion 98. [PubMed: 18496184]

22. Wilk JE, Herrell RK, Wynn GH, Riviere LA, Hoge CW. Mild traumatic brain injury (concussion), posttraumatic stress disorder, and depression in U.S. soldiers involved in combat deployments: association with postdeployment symptoms. *Psychosom Med*. 2012 Apr; 74(3):249–57. [PubMed: 22366583]
23. Fischer BL, Parsons M, Durgerian S, et al. Neural Activation during Response Inhibition Differentiates Blast from Mechanical Causes of Mild to Moderate Traumatic Brain Injury. *Journal of neurotrauma*. 2014 Jan 15; 31(2):169–79. [PubMed: 24020449]
24. Corsellis JA, Bruton CJ, Freeman-Browne D. The aftermath of boxing. *Psychological medicine*. 1973 Aug; 3(3):270–303. [PubMed: 4729191]
25. Stern RA, Daneshvar DH, Baugh CM, et al. Clinical presentation of chronic traumatic encephalopathy. *Neurology*. 2013 Sep 24; 81(13):1122–9. [PubMed: 23966253]
26. Chen H, Richard M, Sandler DP, Umbach DM, Kamel F. Head injury and amyotrophic lateral sclerosis. *American journal of epidemiology*. 2007 Oct 1; 166(7):810–6. [PubMed: 17641152]
27. Rosso SM, Landweer EJ, Houterman M, Donker Kaat L, van Duijn CM, van Swieten JC. Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study. *J Neurol Neurosurg Psychiatry*. 2003 Nov; 74(11):1574–6. [PubMed: 14617722]
28. Kalkonde YV, Jawaid A, Qureshi SU, et al. Medical and environmental risk factors associated with frontotemporal dementia: a case-control study in a veteran population. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2012 May; 8(3):204–10.
29. Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH. Risk of Parkinson's disease after hospital contact for head injury: population based case-control study. *Bmj*. 2008; 337:a2494. [PubMed: 19074944]
30. Goldman SM, Kamel F, Ross GW, et al. Head injury, alpha-synuclein Rep1, and Parkinson's disease. *Ann Neurol*. 2012 Jan; 71(1):40–8. [PubMed: 22275250]
31. Lee PC, Bordelon Y, Bronstein J, Sinsheimer JS, Farrer M, Ritz B. Head injury, alpha-synuclein genetic variability and Parkinson's disease. *European journal of neurology : the official journal of the European Federation of Neurological Societies*. 2014 Nov 5.
32. Lee PC, Bordelon Y, Bronstein J, Ritz B. Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease. *Neurology*. 2012 Nov 13; 79(20):2061–6. [PubMed: 23150532]
33. Carroll LJ, Cassidy JD, Peloso PM, et al. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. *Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine*. 2004 Feb.(43 Suppl):84–105.
34. Godbolt AK, Cancelliere C, Hincapie CA, et al. Systematic Review of the Risk of Dementia and Chronic Cognitive Impairment After Mild Traumatic Brain Injury: Results of the International Collaboration on Mild Traumatic Brain Injury Prognosis. *Archives of physical medicine and rehabilitation*. 2014 Mar; 95(3S):S245–S56. [PubMed: 24581910]
35. Mehta KM, Ott A, Kalmijn S, et al. Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study. *Neurology*. 1999 Dec 10; 53(9):1959–62. [PubMed: 10599765]
36. Graves AB, White E, Koepsell TD, et al. The association between head trauma and Alzheimer's disease. *American journal of epidemiology*. 1990 Mar; 131(3):491–501. [PubMed: 2405648]
37. Schofield PW, Tang M, Marder K, et al. Alzheimer's disease after remote head injury: an incidence study. *J Neurol Neurosurg Psychiatry*. 1997 Feb; 62(2):119–24. [PubMed: 9048710]
38. Helmes E, Ostbye T, Steenhuis RE. Incremental contribution of reported previous head injury to the prediction of diagnosis and cognitive functioning in older adults. *Brain injury : [BI]*. 2011; 25(4):338–47.
39. Lee YK, Hou SW, Lee CC, Hsu CY, Huang YS, Su YC. Increased risk of dementia in patients with mild traumatic brain injury: a nationwide cohort study. *PloS one*. 2013; 8(5):e62422. [PubMed: 23658727]
40. Nordstrom P, Michaelsson K, Gustafson Y, Nordstrom A. Traumatic brain injury and young onset dementia: a nationwide cohort study. *Ann Neurol*. 2014 Mar; 75(3):374–81. [PubMed: 24812697]
41. Gardner RC, Burke JF, Nettiksimmons J, Kaup A, Barnes DE, Yaffe K. Dementia risk after traumatic brain injury versus non brain trauma: the role of age and severity. *JAMA neurology*. 2014 in press.

42. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. *Neurology*. 1996 May; 46(5):1275–84. [PubMed: 8628466]
43. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. *Mov Disord*. 1999 Nov; 14(6):928–39. [PubMed: 10584666]
44. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA. Head trauma preceding PD: a case-control study. *Neurology*. 2003 May 27; 60(10):1610–5. [PubMed: 12771250]
45. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW. Head injury and Parkinson's disease risk in twins. *Ann Neurol*. 2006 Jul; 60(1):65–72. [PubMed: 16718702]
46. Lehman EJ, Hein MJ, Baron SL, Gersic CM. Neurodegenerative causes of death among retired National Football League players. *Neurology*. 2012 Nov 6; 79(19):1970–4. [PubMed: 22955124]
47. Savica R, Parisi JE, Wold LE, Josephs KA, Ahlskog JE. High school football and risk of neurodegeneration: a community-based study. *Mayo Clinic proceedings*. 2012 Apr; 87(4):335–40. [PubMed: 22469346]
48. McKee AC, Gavett BE, Stern RA, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. *Journal of neuropathology and experimental neurology*. 2010 Sep; 69(9):918–29. [PubMed: 20720505]
49. Omalu B, Bailes J, Hamilton RL, et al. Emerging histomorphologic phenotypes of chronic traumatic encephalopathy in American athletes. *Neurosurgery*. 2011 Jul; 69(1):173–83. discussion 83. [PubMed: 21358359]
50. Martland HS. Punch drunk. *Journal of the American Medical Association*. 1928; 91(15):1103–7.
51. Taylor RB. Traumatic encephalopathy from boxing. *British medical journal*. 1953 Jan 24; 1(4803):200–1. [PubMed: 13009140]
52. Millsbaugh J. Dementia Pugilistica. *US Nav Med Bull*. 1937; 35:297–303.
53. Parker HL. Traumatic Encephalopathy ('Punch Drunk') of Professional Pugilists. *The Journal of neurology and psychopathology*. 1934 Jul; 15(57):20–8. [PubMed: 21610785]
54. Constantinidis J, Tissot R. Generalized Alzheimer's neurofibrillary lesions without senile plaques. (Presentation of one anatomic-clinical case). *Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie*. 1967; 100(1):117–30.
55. Roberts, AH. Brain damage in boxers: A study of the prevalence of traumatic encephalopathy among ex-professional boxers. Pitman Medical & Scientific Publishing Co., Ltd; 1969.
56. McCrory P, Meeuwisse WH, Kutcher JS, Jordan BD, Gardner A. What is the evidence for chronic concussion-related changes in retired athletes: behavioural, pathological and clinical outcomes? *British journal of sports medicine*. 2013 Apr; 47(5):327–30. [PubMed: 23479493]
57. Hazrati LN, Tartaglia MC, Diamandis P, et al. Absence of chronic traumatic encephalopathy in retired football players with multiple concussions and neurological symptomatology. *Frontiers in human neuroscience*. 2013; 7:222. [PubMed: 23745112]
58. Jordan BD. The clinical spectrum of sport-related traumatic brain injury. *Nature reviews Neurology*. 2013 Apr; 9(4):222–30.
59. Jordan BD. Chronic Traumatic Encephalopathy and Other Long-term Sequelae. *Continuum*. 2014 Dec; 20(6 Sports Neurology):1588–604. [PubMed: 25470162]
60. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. *The Lancet Neurology*. 2015 Jan; 14(1):114–24. [PubMed: 25496902]
61. Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. *PloS one*. 2012; 7(4):e33606. [PubMed: 22496755]
62. Bernick C, Banks S, Phillips M, et al. Professional fighters brain health study: rationale and methods. *American journal of epidemiology*. 2013 Jul 15; 178(2):280–6. [PubMed: 23735309]
63. Mac Donald CL, Johnson AM, Wierzechowski L, et al. Prospectively Assessed Clinical Outcomes in Concussive Blast vs Nonblast Traumatic Brain Injury Among Evacuated US Military Personnel. *JAMA neurology*. 2014 Aug 1; 71(8):994–1002. [PubMed: 24934200]

64. Guo Z, Cupples LA, Kurz A, et al. Head injury and the risk of AD in the MIRAGE study. *Neurology*. 2000 Mar 28; 54(6):1316–23. [PubMed: 10746604]
65. Jordan BD. Chronic traumatic brain injury associated with boxing. *Seminars in neurology*. 2000; 20(2):179–85. [PubMed: 10946737]
66. Schmidt S, Kwee LC, Allen KD, Oddone EZ. Association of ALS with head injury, cigarette smoking and APOE genotypes. *J Neurol Sci*. 2010 Apr 15; 291(1-2):22–9. [PubMed: 20129626]
67. Jordan BD, Relkin NR, Ravdin LD, Jacobs AR, Bennett A, Gandy S. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. *JAMA : the journal of the American Medical Association*. 1997 Jul 9; 278(2):136–40.
68. Lolekha P, Phanthumchinda K, Bhidayasiri R. Prevalence and risk factors of Parkinson's disease in retired Thai traditional boxers. *Mov Disord*. 2010 Sep 15; 25(12):1895–901. [PubMed: 20669292]
69. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. *Journal of neuropathology and experimental neurology*. 2009 Jul; 68(7):709–35. [PubMed: 19535999]
70. Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. *Clinics in sports medicine*. 2011 Jan; 30(1):179–88. xi. [PubMed: 21074091]
71. Field M, Collins MW, Lovell MR, Maroon J. Does age play a role in recovery from sports-related concussion? A comparison of high school and collegiate athletes. *The Journal of pediatrics*. 2003 May; 142(5):546–53. [PubMed: 12756388]
72. Pullela R, Raber J, Pfankuch T, et al. Traumatic injury to the immature brain results in progressive neuronal loss, hyperactivity and delayed cognitive impairments. *Developmental neuroscience*. 2006; 28(4-5):396–409. [PubMed: 16943663]

Abbreviations

AD	Alzheimer's disease
ALS	amyotrophic lateral sclerosis
CTE	chronic traumatic encephalopathy
MTBI	mild traumatic brain injury
PD	Parkinson's disease
TBI	traumatic brain injury

Highlights

- Mild traumatic brain injury (MTBI) is extremely common.
- Some studies have found an association between MTBI and neurodegenerative diseases.
- Chronic traumatic encephalopathy (CTE) is associated with repetitive MTBI.
- Prevalence of CTE is unknown as it can only be diagnosed on autopsy.
- Large prospective longitudinal studies of MTBI and neurodegeneration are needed.

Table 1
Methodological Challenges of Epidemiological Studies of CTE

Challenge	Consequence
Lack of consensus clinical criteria for CTE.	Prevalence/incidence can only be inferred from autopsy series, which are often limited by referral bias.
Variable definitions for MTBI used in prior studies.	Hinders comparison across studies.
Objective quantification/measurement of repetitive MTBI exposure is difficult.	Population studied may have very heterogeneous MTBI exposures. Amount of MTBI exposure necessary to produce pathology is unknown.
Recall bias	Symptomatic patients may be more likely to report MTBI exposure or less likely to recall MTBI exposure (if memory is affected).
Selection or referral bias	Results are not broadly applicable to general population
Finding the appropriate control group is difficult.	Potential for confounding as MTBI-exposed populations may differ from healthy controls in many ways besides MTBI exposure.
Secular trends: frequency and quality of MTBI exposure has changed dramatically among athletes and military personnel over the past century	Unclear to what degree older studies may be applied to modern patients
Cohort effects: MTBI sustained in American football may differ considerably from MTBI sustained in boxing or combat.	Unclear to what degree studies of one cohort of patients exposed to repetitive MTBI may be applied to other cohorts.
CTE symptoms may not appear until years or decades following MTBI exposure	Prospective studies from time of exposure to symptom onset may take decades to yield results. Retrospective studies may be influenced by recall bias or poorly quantified exposure.

Abbreviations: CTE = chronic traumatic encephalopathy; MTBI = mild traumatic brain injury

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2
Definitions of Pertinent Epidemiological Concepts

Epidemiological Term	Definition
Selection/Referral Bias	This is a source of systematic error in which study participation is not random and therefore is not representative of the entire population of interest. This may confound and/or limit generalizability of the results.
Recall/reporting bias	This is a type of systematic error in which the accuracy of reporting of prior events systematically differs between study participants (e.g. between cases and controls). This may be of particular concern in retrospective studies based on chart review but may also effect any study measurement that relies upon self or informant report.
Confounding	The observed association between a predictor and an outcome is not due to a causal relationship. Rather, the association is due to a third factor, which influences both the predictor and outcome. This concern can be mitigated by adjusting analyses for confounders or matching cases and controls based on confounders.
Reverse-causation	The outcome is the cause of the predictor. Thus, while the predictor and outcome will be associated, the causal arrow is in the reverse direction from what is expected/hypothesized.
Secular trend	Changes in characteristics of a disease over time, which may be due to changing external factors.
Cohort effect	Unique characteristics of a disease in a specific cohort due to a shared exposure, year of birth, or other shared life experience.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3
Possible Risk Factors for Post-TBI Dementia, PD, and CTE

Risk Factor Category	Dementia	PD	CTE
Demographic	Increasing age ^{40, 41}	Increasing age ⁶⁸	Increasing age ⁸
Genetic	APOE allele ⁶⁴	Alpha-synuclein genotype ^{30, 31}	Competing results for APOE allele ^{8, 48, 67}
TBI factors	>1 TBI ⁴¹ More severe TBI ^{40, 41} Exposure to contact sports ⁴⁶	>1 TBI ^{45, 68} More severe TBI ^{3, 5} Exposure to contact sports ^{52, 46}	Repetitive MTBI ^{8, 49, 69} Repetitive sub-concussive head trauma ⁷⁰ Exposure ⁶⁹ and duration of exposure ⁵⁵ to contact sports
Other environmental exposures		Paraquat exposure ³²	

Abbreviations: APOE = apolipoprotein; TBI = traumatic brain injury. Other abbreviations per Table 1.